Cancer Derived Organoids

#CancerDerivedOrganoids

Cancer-Derived Organoids (CDOs) are three-dimensional (3D) culture systems grown from patient tumor cells.

They replicate many aspects of the original tumor, including its structure, genetic makeup, and behavior.

These organoids are powerful tools in cancer research, precision medicine, and drug development.

What Are Cancer-Derived Organoids?

• Definition: Miniature tumor-like structures grown in vitro from cancerous tissue.

• Source: Derived directly from patient tumors (biopsy or surgical specimens).

• Culture: Maintained in a supportive 3D matrix (like Matrigel) and specialized growth media.

• Features:

• Retain tumor heterogeneity

Reflect mutational landscape and histopathology

• Can be passaged and biobanked

How Are They Made?

1. Tissue acquisition – from primary or metastatic tumors.

2. Tissue dissociation – into single cells or small clusters.

3. 3D culture embedding – in extracellular matrix gels.

4. Culture expansion – using tumor-specific growth factors.

5. Validation – through sequencing and histology comparison to the original tumor.

Key Applications

Area Use Case

Personalized Medicine Screening cancer drugs for individual patients to predict response.

Drug Development High-throughput testing of anticancer compounds.

Cancer Biology Studying tumor progression, resistance mechanisms, and heterogeneity.

Immuno-oncology Co-culturing with immune cells (e.g. T-cells or CAR-T) to evaluate response.

Biobanking Creating living cancer tissue libraries for future research.

Examples of Use

• Colorectal cancer: One of the most established organoid models.

• Pancreatic ductal adenocarcinoma: Organoids help study its aggressive nature and drug resistance.

• Lung, breast, prostate cancers: Increasingly used to model tumor subtypes and test therapies.

Advantages

Maintains patient-specific tumor characteristics.

• Enables real-time drug screening.

• More predictive than traditional 2D cultures or cell lines.

Limitations

• May lack immune and stromal components (though co-culture methods are evolving).

• Technically demanding to establish from some tumor types.

• Not always suitable for high-throughput or long-term storage without modification.

Would you like specific examples from recent research or information on how they’re being used clinically?

#SamsungBio

#Organoids

#FDA